Developer docs
API playgroundTry for free, no card

Search company profiles

Tocagen

Full company profile

uuid0004waw

Namestring
Tocagen
Websiteurl
tocagen.com
Company typeenum
Private
Founded yearint
2007
Descriptiontext

Tocagen's web presence has lapsed: the tocagen.com domain registration has expired and the URL currently resolves to a Namecheap domain parking page that displays no company content, products, or services. The supplied source data contains no functional description of the company's business, no product or service catalog, no technology stack, no customer information, no management team, no funding history, no pricing, and no operational or geographic footprint. The only directly observable artifact is the expired domain itself, which the source data flags as evidence that the company is likely no longer actively maintaining its online presence. Ownership structure, incorporation details, founding date, public/private status, and operating geographies are all absent from the supplied data and cannot be determined from the parking-page content.

Because no operational information is available in the supplied sources, this description is restricted to what the evidence directly supports: the company name, the expired status of its primary domain, and the absence of any other verifiable business, technology, or commercial detail. No claims about the company's products, market, customers, business model, or technology can be made without exceeding the evidence provided.

Short descriptiontext

Tocagen is a company whose primary domain (tocagen.com) has expired and now displays a Namecheap parking page; no products, customers, operations, or business activity are documented in the available source data.

Operating statusenum
Closed
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Product category
Unknown
Social media profiles3 records
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

No information about Tocagen's core offerings is available from the source data. The company's website domain (tocagen.com) has expired and currently displays a Namecheap domain parking page, which provides no product or service information.

Differentiator
Functional benefit
Problem solved
Recent move1 record

Each record includes

Date, Type, Title, Description, Source

Expansion highlight1 record

Each record includes

Type, Description

Peers5 records
1bluebird bio
TypeBroad incumbent
Description

Established gene therapy company across multiple therapeutic areas including oncology — broad incumbent in the same gene therapy category Tocagen operated in.

2GenVec
TypeEmerging player
Description

Developed adenoviral vector and oncology vaccine programs using viral delivery for cancer treatment — closely comparable viral vector oncology category.

3Advantagene
TypeDirect peer
Description

Developed gene-mediated cytotoxic immunotherapy (GMCI) for cancer, using a viral vector platform analogous to Tocagen's retroviral gene transfer approach.

4VBL Therapeutics
TypeEmerging player
Description

Clinical-stage oncology company developing gene therapy-based treatments, including vascular-targeted platforms for solid tumors — comparable cancer gene therapy niche.

5Ziopharm Oncology
TypeDirect peer
Description

Clinical-stage oncology company using gene therapy and engineered cell therapy approaches — closely overlaps with Tocagen's category of viral vector-based cancer therapeutics.

Market position
Strengths1 record

Each record includes

Headline, Details, Source

Weaknesses2 records

Each record includes

Headline, Details, Source

Competitive moat1 record

Each record includes

Type, Details

Key risks3 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

No data
Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds11 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors1 record

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tocagen

Unknowntocagen.com

Tocagen is a company whose primary domain (tocagen.com) has expired and now displays a Namecheap parking page; no products, customers, operations, or business activity are documented in the available source data.

What Tocagen does

Tocagen's web presence has lapsed: the tocagen.com domain registration has expired and the URL currently resolves to a Namecheap domain parking page that displays no company content, products, or services. The supplied source data contains no functional description of the company's business, no product or service catalog, no technology stack, no customer information, no management team, no funding history, no pricing, and no operational or geographic footprint. The only directly observable artifact is the expired domain itself, which the source data flags as evidence that the company is likely no longer actively maintaining its online presence. Ownership structure, incorporation details, founding date, public/private status, and operating geographies are all absent from the supplied data and cannot be determined from the parking-page content.

Because no operational information is available in the supplied sources, this description is restricted to what the evidence directly supports: the company name, the expired status of its primary domain, and the absence of any other verifiable business, technology, or commercial detail. No claims about the company's products, market, customers, business model, or technology can be made without exceeding the evidence provided.

Tocagen firmographics

Firmographics
Name
Tocagen
Website
https://tocagen.com
Company type
Private
Founded year
2007
Operating status
Closed
Headcount range
1–10 employees
Short description
Tocagen is a company whose primary domain (tocagen.com) has expired and now displays a Namecheap parking page; no products, customers, operations, or business activity are documented in the available source data.
Ownership category
akta.pro rank

Where Tocagen is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Markets served

Tocagen business model

Business model
GTM type
B2B
Offering type
Services

Tocagen product offering

Product offering

Core offering

No information about Tocagen's core offerings is available from the source data. The company's website domain (tocagen.com) has expired and currently displays a Namecheap domain parking page, which provides no product or service information.

Differentiator

Problem solved

Functional benefit

Tocagen technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Tocagen partnerships and signals

Strategic signal

Recent moves1 record

Expansion highlights1 record

Tocagen competitors and assessment

Company assessment

Broad incumbents

  • bluebird bio: Established gene therapy company across multiple therapeutic areas including oncology — broad incumbent in the same gene therapy category Tocagen operated in.

Emerging players

  • GenVec: Developed adenoviral vector and oncology vaccine programs using viral delivery for cancer treatment — closely comparable viral vector oncology category.
  • VBL Therapeutics: Clinical-stage oncology company developing gene therapy-based treatments, including vascular-targeted platforms for solid tumors — comparable cancer gene therapy niche.

Direct peers

  • Advantagene: Developed gene-mediated cytotoxic immunotherapy (GMCI) for cancer, using a viral vector platform analogous to Tocagen's retroviral gene transfer approach.
  • Ziopharm Oncology: Clinical-stage oncology company using gene therapy and engineered cell therapy approaches — closely overlaps with Tocagen's category of viral vector-based cancer therapeutics.

Market position

Strengths1 record

Weaknesses2 records

Competitive moat1 record

Key risks3 records

Customer concentration

Tocagen social profiles

Digital presence

Tocagen financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tocagen leadership team

Management profile

Number of profiles

Tocagen funding detail

Funding detail

Funding overview

Funding rounds11 records

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tocagen M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tocagen

What does Tocagen do?

No information about Tocagen's core offerings is available from the source data. The company's website domain (tocagen.com) has expired and currently displays a Namecheap domain parking page, which provides no product or service information.

When was Tocagen founded?

Tocagen was founded in 2007. It employs 1 to 10 people.

Where is Tocagen based?

Tocagen is headquartered in San Diego, United States, in the North America region.

Who are Tocagen's main competitors?

bluebird bio is listed as a broad incumbent. Emerging players are GenVec and VBL Therapeutics. Direct peers are Advantagene and Ziopharm Oncology.

Does Tocagen have an API?

No public API is recorded for Tocagen.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
The Pharma LetterForte’s FB102 achieves statistically-significant improvement in vitiligoForte Biosciences shares rose 78% to $3.70 after announcing positive results from its FB102 phase Ib study in vitiligo. The company gained rights to the compound following its 2020 acquisition of Tocagen for about $25 million.PR NewswireTocagen Announces Change to Virtual Format for Special Meeting of StockholdersTocagen Inc. announced it is changing its special meeting of stockholders, originally scheduled for June 12, 2020, to a virtual-only format due to COVID-19 public health concerns and related government orders. The meeting concerns a previously announced proposed merger with Forte Biosciences, Inc., and stockholders can attend and vote electronically via a live audio webcast. The date, time, and other meeting details remain unchanged.PR NewswireDenovo Biopharma To Acquire Tocagen's Entire Replicating Gene Therapy Platform and Related AssetsDenovo Biopharma LLC announced the acquisition of Tocagen's retroviral replicating vector platform, including the gene therapy DB107 and several early-stage immunooncology programs, pending the close of Tocagen's merger with Forte Biosciences. The acquisition will expand Denovo's portfolio into gene therapy and immunooncology while leveraging Denovo's biomarker platform to identify patient subsets who may respond to DB107, which showed mixed results in a Phase 3 trial for recurrent high grade glioma. Denovo aims to position itself as a leader in neuro-oncology with the combined assets of DB107 and DB102.PR NewswireTocagen Reports First Quarter 2020 Financial ResultsTocagen Inc. reported a first quarter 2020 net loss of $10.3 million, significantly improved from a $17.1 million loss in Q1 2019, while R&D expenses fell to $3.1 million from $12.4 million due to clinical trial wind-down and workforce reduction. The company also announced a pending all-stock merger with Forte Biosciences Inc., expected to close in Q2 2020 pending stockholder and regulatory approvals, after which the combined company will operate as Forte Biosciences and trade under ticker FBRX. Cash position declined to $14.2 million at March 31, 2020, from $21.8 million at year-end 2019.PR NewswireThinking about buying stock in Aphria, Chesapeake Energy Corp, JetBlue Airways, Tocagen, or Verizon?InvestorsObserver issued PriceWatch Alerts for Aphria, Chesapeake Energy Corp, JetBlue Airways, Tocagen, and Verizon based on its proprietary scoring methodology. The alerts evaluate these stocks using short-term technical, long-term technical, and fundamental factors to determine investment suitability. This announcement serves as a routine distribution of stock ratings from the financial data provider.PR NewswireThinking about buying stock in Aurora Cannabis, Barrick Gold Corp, Micron, Sprouts Farmers Market, or Tocagen?InvestorsObserver issued PriceWatch Alerts for Aurora Cannabis, Barrick Gold Corp, Micron, Sprouts Farmers Market, and Tocagen based on their proprietary scoring methodology. The alerts evaluate these stocks using short-term technical, long-term technical, and fundamental factors to determine investment suitability. This is a routine distribution of market analysis data.PR NewswireTocagen and Forte Biosciences Announce MergerTocagen Inc. and Forte Biosciences, Inc. announced they have entered into a definitive agreement to merge in an all-stock transaction, with the combined company to operate under the name Forte Biosciences and trade on Nasdaq under the ticker symbol FBRX. An investor syndicate including Alger, BVF Partners LP and OrbiMed will invest $14 million in the combined company prior to closing, bringing total expected cash to approximately $25 million. The merger, expected to close in Q2 2020 subject to stockholder approval and customary conditions, will focus on advancing Forte's lead asset FB-401, a live biotherapeutic for atopic dermatitis, into a Phase 2 trial.PR NewswireTocagen to Participate in Two Upcoming Investor ConferencesTocagen Inc., a clinical-stage cancer gene therapy company, announced that CEO Marty Duvall will present at the Baird 2019 Global Healthcare Conference in New York on September 4 and participate in Citi's 14th Annual Biotech Conference in Boston on September 5. The presentations will be webcast live and archived on the company's website for 30 days. The announcement is part of routine investor relations activity as the company continues its Phase 3 trial (Toca 5) for Toca 511 & Toca FC in recurrent high grade glioma.PR NewswireTocagen Reports Second Quarter 2019 Financial Results and Business UpdatesTocagen Inc. reported second quarter 2019 financial results, posting a net loss of $17.1 million compared to a net loss of $16.1 million in Q2 2018, with R&D expenses decreasing to $12.0 million from $12.8 million year-over-year while G&A expenses increased to $4.9 million from $2.6 million. The company's cash position declined to $68.3 million as of June 30, 2019, from $96.1 million at year-end 2018. Clinical development continues as planned with the pivotal Toca 5 Phase 3 trial progressing toward final analysis, a rolling BLA filing pending positive data, and a NRG Oncology-sponsored Phase 2/3 trial in newly diagnosed glioblastoma expected to initiate by year-end 2019.PR NewswireTocagen to Report Second Quarter 2019 Financial Results and Business Updates on Thursday, August 8Tocagen Inc., a clinical-stage cancer-selective gene therapy company, announced it will report its second quarter 2019 financial results and business updates on Thursday, August 8, 2019, after the close of U.S. financial markets. The company's lead product candidate, Toca 511 & Toca FC, is currently under evaluation in a pivotal Phase 3 trial for recurrent high grade glioma and has received Breakthrough Therapy Designation from the U.S. FDA and PRIME designation from the European Medicines Agency. This is a routine advance announcement of an upcoming earnings release.